PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 ProMIS Neurosciences (NASDAQ: PMN ) just reported results for the first quarter of 2024. ProMIS Neurosciences reported earnings per share of -19 cents. This was above the analyst estimate for EPS of -20 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 appeared first on InvestorPlace .
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024
ProMIS Neurosciences Advances Alzheimer’s Treatment with PMN310 ProMIS Neurosciences (PMN) has provided an announcement. ProMIS Neurosciences Inc. announced findings from a recent study suggesting that the effec…
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS | PMN Stock News ProMIS Neurosciences Inc. announces promising preclinical data supporting TDP-43 misfolding-specific epitope as a potential therapeutic target for ALS. The study reveals the interaction between misfolded TDP-43 and SOD1, leading to motor neuron damage in ALS. PMN267 shows potential as a treatment for ALS, with data published in a prestigious journal.
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that company management will participate in three upcoming investor conferences:
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 ProMIS Neurosciences (NASDAQ: PMN ) just reported results for the fourth quarter of 2023. ProMIS Neurosciences reported earnings per share of -9 cents. This was above the analyst estimate for EPS of -17 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 appeared first on InvestorPlace .
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio | PMN Stock News ProMIS Neurosciences, Inc. (PMN) secures key U.S. and international patent allowances for its monoclonal antibody therapeutic, PMN310, targeting toxic misfolded proteins in Alzheimer''s disease. The patents cover composition of matter and method of use for PMN310, enhancing its protection globally. The company''s CEO highlights the significance of these patents in fortifying their innovative approach to treating neurodegenerative diseases.